Tarsus Pharmaceuticals Inc expected to post a loss of 94 cents a share - Earnings Preview

Tarsus Pharmaceuticals

06/05/2023 03:02

* Tarsus Pharmaceuticals Inc  TARS.OQ   TARS.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 8 (estimated). 
    * The Irvine California-based  company is expected to report
 a
479.8% increase in revenue to $3.125 million from $539 thousand
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Tarsus
Pharmaceuticals
Inc is for a loss of 94 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $43​, above​ its last closing price
of $15.35. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              -0.69      -0.49     Beat    29
 Sep. 30 2022  -0.88       -0.97      -0.84     Beat    13.7
 Jun. 30 2022  -0.61       -0.59      -0.24     Beat    59.4​
 Mar. 31 2022  -1.06       -0.92      -0.98     Missed  -6.8
 ​​Dec.        -0.76       -0.73      -0.72     Beat    1
 31 2021                                                
 Sep. 30 2021  -0.41       -0.43      -0.76     Missed  -75.1​
 Jun. 30 2021  -0.40       -0.48      0.33      Beat    169.2
 Mar. 31 2021  -0.73       -0.64      0.47      Beat    173.4
 This summary was machine generated May 6 at 02:02 GMT.  All
figures in US dollars  unless otherwise stated